TRN 257
Alternative Names: TRN-257Latest Information Update: 03 Mar 2023
At a glance
- Originator Tris Pharma
- Class Sleep disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Narcolepsy
Most Recent Events
- 11 Jan 2023 Clinical trials in Narcolepsy in USA (unspecified route), before January 2023 (Tris Pharma pipeline, January 2023)